Zanacea Biotec Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 25 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.30 M
- Satisfied Charges ₹ 5.00 M
- Revenue Growth -4.64%
- Profit Growth -14.61%
- Ebitda -93.49%
- Net Worth 27.27%
- Total Assets 6.27%
About Zanacea Biotec
Zanacea Biotec Private Limited (ZBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 23 April 1999 and has a history of 25 years and nine months. Its registered office is in Sikar, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.30 M. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Sharma and Sampat Sharma serve as directors at the Company.
Company Details
-
Location
Sikar, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ1999PTC015559
-
Company No.
015559
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Apr 1999
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Zanacea Biotec?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Sharma
|
Director | 23-Apr-1999 | Current |
|
Sampat Sharma
|
Director | 14-Jun-2007 | Current |
Financial Performance of Zanacea Biotec.
Zanacea Biotec Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 4.64% decrease. The company also saw a substantial fall in profitability, with a 14.61% decrease in profit. The company's net worth Soared by an impressive increase of 27.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zanacea Biotec?
In 2019, Zanacea Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.30 M
₹5.00 M
Charges Breakdown by Lending Institutions
- United Bank Of India : 0.53 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Sep 2016 | United Bank Of India | ₹5.30 M | Open |
| 28 Feb 2013 | Axis Bank Ltd. | ₹5.00 M | Satisfied |
How Many Employees Work at Zanacea Biotec?
Unlock and access historical data on people associated with Zanacea Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zanacea Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zanacea Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.